BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30594749)

  • 1. The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma.
    Youssef G; Gillett C; Rampling D; Chagtai T; Virasami A; Barton J; Edwards D; Sebire N; Anderson J; Montano X
    Hum Pathol; 2019 Apr; 86():182-192. PubMed ID: 30594749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: a potential novel prognostic marker for breast cancer.
    Youssef G; Gillett C; Agbaje O; Crompton T; Montano X
    Mod Pathol; 2014 Mar; 27(3):361-74. PubMed ID: 23948750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Potential Prognostic Gene Signature Associated with p53-Dependent NTRK1 Activation and Increased Survival of Neuroblastoma Patients.
    Currie D; Wong N; Zane I; Rix T; Vardakastanis M; Claxton A; Ong KKV; Macmorland W; Poivet A; Brooks A; Niola P; Huntley D; Montano X
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation.
    Montano X
    Oncogene; 2009 Oct; 28(43):3787-800. PubMed ID: 19749791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of SARS-CoV-2 infection associated cell entry proteins ACE2, CD147, PPIA, and PPIB in datasets from non SARS-CoV-2 infected neuroblastoma patients, as potential prognostic and infection biomarkers in neuroblastoma.
    Bergsneider B; Bailey E; Ahmed Y; Gogineni N; Huntley D; Montano X
    Biochem Biophys Rep; 2021 Sep; 27():101081. PubMed ID: 34307909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of MDM2 gene expression in childhood neuroblastoma.
    Inomistova MV; Svergun NM; Khranovska NM; Skachkova OV; Gorbach OI; Klymnyuk GI
    Exp Oncol; 2015 Jun; 37(2):111-5. PubMed ID: 26112937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c.1810C>T polymorphism of NTRK1 gene is associated with reduced survival in neuroblastoma patients.
    Lipska BS; Drozynska E; Scaruffi P; Tonini GP; Izycka-Swieszewska E; Zietkiewicz S; Balcerska A; Perek D; Chybicka A; Biernat W; Limon J
    BMC Cancer; 2009 Dec; 9():436. PubMed ID: 20003389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of NTRK family gene expression in neuroblastomas.
    Light JE; Koyama H; Minturn JE; Ho R; Simpson AM; Iyer R; Mangino JL; Kolla V; London WB; Brodeur GM
    Pediatr Blood Cancer; 2012 Aug; 59(2):226-32. PubMed ID: 21990266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications.
    Li Z; Takenobu H; Setyawati AN; Akita N; Haruta M; Satoh S; Shinno Y; Chikaraishi K; Mukae K; Akter J; Sugino RP; Nakazawa A; Nakagawara A; Aburatani H; Ohira M; Kamijo T
    Oncogene; 2018 May; 37(20):2714-2727. PubMed ID: 29507419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
    de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
    Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant promoter 2 methylation‑mediated downregulation of protein tyrosine phosphatase, non‑receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
    Liu L; Zhang S; Liu X; Liu J
    Mol Med Rep; 2019 Apr; 19(4):3273-3282. PubMed ID: 30816454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
    Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
    Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical expressions of Cap43 and Mina53 proteins in neuroblastoma.
    Fukahori S; Yano H; Tsuneoka M; Tanaka Y; Yagi M; Kuwano M; Tajiri T; Taguchi T; Tsuneyoshi M; Kojiro M
    J Pediatr Surg; 2007 Nov; 42(11):1831-40. PubMed ID: 18022432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
    Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
    Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of P27(KIP1) is prognostic and independent of MYCN amplification in human neuroblastoma.
    Bergmann E; Wanzel M; Weber A; Shin I; Christiansen H; Eilers M
    Int J Cancer; 2001 May; 95(3):176-83. PubMed ID: 11307151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of promoter DNA methylation in patients with childhood neuroblastoma.
    Lau DT; Hesson LB; Norris MD; Marshall GM; Haber M; Ashton LJ
    Clin Cancer Res; 2012 Oct; 18(20):5690-700. PubMed ID: 22929802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The von Hippel-Lindau tumor suppressor gene expression level has prognostic value in neuroblastoma.
    Hoebeeck J; Vandesompele J; Nilsson H; De Preter K; Van Roy N; De Smet E; Yigit N; De Paepe A; Laureys G; Påhlman S; Speleman F
    Int J Cancer; 2006 Aug; 119(3):624-9. PubMed ID: 16506218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of biologic factors on the surgical decision in advanced neuroblastoma.
    Hsu WM; Jen YM; Lee H; Kuo ML; Tsao PN; Chen CN; Lai DM; Lin MT; Lai HS; Chen WJ; Hsieh FJ
    Ann Surg Oncol; 2006 Feb; 13(2):238-44. PubMed ID: 16418884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.